AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Share Issue/Capital Change Jun 15, 2015

3232_rns_2015-06-15_3232367d-db44-48b7-a4b0-623e009f95d1.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Disclosure 325207

Orion - Company Announcement

229,000 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE 15 JUNE 2015 at 8.40 a.m. EEST 229,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 229,000 A shares have been converted into 229,000 B shares. The conversion has been entered into the Trade Register on 15 June 2015. The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 39,625,774 A shares and 101,632,054 B shares. Orion Corporation Olli Huotari Jari Karlson SVP, Corporate Functions CFO Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki. [HUG#1928389]

Talk to a Data Expert

Have a question? We'll get back to you promptly.